AAPL296.17+1.87 (+0.64%) ▲|ABBV233.39-1.37 (-0.58%) ▼|ABT91.16+0.63 (+0.69%) ▲|ACN130.37+3.36 (+2.65%) ▲|ADBE198.66+1.23 (+0.62%) ▲|AMAT578.80-7.08 (-1.21%) ▼|AMD514.52-5.33 (-1.03%) ▼|AMGN351.58+4.57 (+1.32%) ▲|AMT175.26-4.13 (-2.30%) ▼|AMZN238.38+4.27 (+1.82%) ▲|AVGO381.94+1.79 (+0.47%) ▲|AXP342.97+5.19 (+1.54%) ▲|BA221.73+5.02 (+2.32%) ▲|BAC57.68-0.24 (-0.41%) ▼|BKNG184.47+15.53 (+9.19%) ▲|BLK991.23-24.11 (-2.37%) ▼|BMY55.08-0.46 (-0.82%) ▼|BNY144.82-2.47 (-1.68%) ▼|BRK-B495.66+2.85 (+0.58%) ▲|C143.98-0.99 (-0.68%) ▼|CAT984.43+0.19 (+0.02%) ▲|CL92.13+0.70 (+0.77%) ▲|CMCSA22.69-0.12 (-0.50%) ▼|COF201.69+3.88 (+1.96%) ▲|COP106.94-3.03 (-2.76%) ▼|COST962.36+4.68 (+0.49%) ▲|CRM153.87+0.45 (+0.29%) ▲|CSCO119.86-1.30 (-1.07%) ▼|CVS101.30-0.27 (-0.27%) ▼|CVX171.69-4.29 (-2.44%) ▼|DE607.48+15.54 (+2.63%) ▲|DHR189.23+10.26 (+5.73%) ▲|DIS102.37-1.16 (-1.12%) ▼|DUK125.54+0.49 (+0.39%) ▲|EMR141.96-1.19 (-0.83%) ▼|FDX312.40-4.85 (-1.53%) ▼|GD346.64-3.71 (-1.06%) ▼|GE366.85+10.38 (+2.91%) ▲|GEV1,057.39+22.41 (+2.17%) ▲|GILD125.60+0.55 (+0.44%) ▲|GM79.77+0.82 (+1.04%) ▲|GOOG345.86-0.22 (-0.06%) ▼|GOOGL346.38+0.29 (+0.08%) ▲|GS1,080.34-14.10 (-1.29%) ▼|HD340.96+16.51 (+5.09%) ▲|HON227.98+5.61 (+2.52%) ▲|IBM264.16-0.78 (-0.29%) ▼|INTC131.24-1.04 (-0.79%) ▼|INTU267.81+9.76 (+3.78%) ▲|ISRG403.88+0.70 (+0.17%) ▲|JNJ239.61+0.53 (+0.22%) ▲|JPM332.93-1.22 (-0.36%) ▼|KO80.91+0.60 (+0.75%) ▲|LIN518.29+6.03 (+1.18%) ▲|LLY1,109.84+2.76 (+0.25%) ▲|LMT497.34-6.34 (-1.26%) ▼|LOW220.94+7.40 (+3.47%) ▲|LRCX367.50-3.83 (-1.03%) ▼|MA495.59+7.52 (+1.54%) ▲|MCD274.87+3.21 (+1.18%) ▲|MDLZ61.99+0.93 (+1.52%) ▲|MDT80.62-0.01 (-0.01%) ▼|META560.45-1.75 (-0.31%) ▼|MMM166.27+4.43 (+2.74%) ▲|MO72.01+0.40 (+0.56%) ▲|MRK120.49+0.89 (+0.74%) ▲|MS221.30-4.73 (-2.09%) ▼|MSFT372.07-1.87 (-0.50%) ▼|MU1,029.53-22.24 (-2.11%) ▼|NEE87.10+0.67 (+0.78%) ▲|NFLX72.74-0.09 (-0.12%) ▼|NKE41.84-0.55 (-1.29%) ▼|NOW94.38-1.57 (-1.63%) ▼|NVDA198.63-1.37 (-0.69%) ▼|ORCL158.00-7.17 (-4.34%) ▼|PEP142.44+0.39 (+0.27%) ▲|PFE24.02-0.71 (-2.85%) ▼|PG152.30+1.44 (+0.95%) ▲|PLTR114.32-2.38 (-2.04%) ▼|PM177.92-0.77 (-0.43%) ▼|QCOM196.60-7.53 (-3.69%) ▼|RTX186.37-0.02 (-0.01%) ▼|SBUX104.22+3.17 (+3.14%) ▲|SCHW91.81-1.36 (-1.46%) ▼|SO95.05+0.12 (+0.13%) ▲|SPG220.53+3.79 (+1.75%) ▲|T22.44-0.38 (-1.64%) ▼|TMO490.90+21.55 (+4.59%) ▲|TMUS182.91-1.66 (-0.90%) ▼|TSLA377.36-4.25 (-1.11%) ▼|TXN303.70-0.66 (-0.22%) ▼|UBER74.02+4.35 (+6.24%) ▲|UNH404.57-4.69 (-1.14%) ▼|UNP260.11+1.50 (+0.58%) ▲|UPS105.06-0.78 (-0.73%) ▼|USB60.14+0.09 (+0.14%) ▲|V332.83+4.35 (+1.32%) ▲|VZ45.68-1.06 (-2.26%) ▼|WFC84.22+0.09 (+0.11%) ▲|WMT119.43+0.01 (+0.01%) ▲|XOM136.36-3.38 (-2.42%) ▼|AAPL296.17+1.87 (+0.64%) ▲|ABBV233.39-1.37 (-0.58%) ▼|ABT91.16+0.63 (+0.69%) ▲|ACN130.37+3.36 (+2.65%) ▲|ADBE198.66+1.23 (+0.62%) ▲|AMAT578.80-7.08 (-1.21%) ▼|AMD514.52-5.33 (-1.03%) ▼|AMGN351.58+4.57 (+1.32%) ▲|AMT175.26-4.13 (-2.30%) ▼|AMZN238.38+4.27 (+1.82%) ▲|AVGO381.94+1.79 (+0.47%) ▲|AXP342.97+5.19 (+1.54%) ▲|BA221.73+5.02 (+2.32%) ▲|BAC57.68-0.24 (-0.41%) ▼|BKNG184.47+15.53 (+9.19%) ▲|BLK991.23-24.11 (-2.37%) ▼|BMY55.08-0.46 (-0.82%) ▼|BNY144.82-2.47 (-1.68%) ▼|BRK-B495.66+2.85 (+0.58%) ▲|C143.98-0.99 (-0.68%) ▼|CAT984.43+0.19 (+0.02%) ▲|CL92.13+0.70 (+0.77%) ▲|CMCSA22.69-0.12 (-0.50%) ▼|COF201.69+3.88 (+1.96%) ▲|COP106.94-3.03 (-2.76%) ▼|COST962.36+4.68 (+0.49%) ▲|CRM153.87+0.45 (+0.29%) ▲|CSCO119.86-1.30 (-1.07%) ▼|CVS101.30-0.27 (-0.27%) ▼|CVX171.69-4.29 (-2.44%) ▼|DE607.48+15.54 (+2.63%) ▲|DHR189.23+10.26 (+5.73%) ▲|DIS102.37-1.16 (-1.12%) ▼|DUK125.54+0.49 (+0.39%) ▲|EMR141.96-1.19 (-0.83%) ▼|FDX312.40-4.85 (-1.53%) ▼|GD346.64-3.71 (-1.06%) ▼|GE366.85+10.38 (+2.91%) ▲|GEV1,057.39+22.41 (+2.17%) ▲|GILD125.60+0.55 (+0.44%) ▲|GM79.77+0.82 (+1.04%) ▲|GOOG345.86-0.22 (-0.06%) ▼|GOOGL346.38+0.29 (+0.08%) ▲|GS1,080.34-14.10 (-1.29%) ▼|HD340.96+16.51 (+5.09%) ▲|HON227.98+5.61 (+2.52%) ▲|IBM264.16-0.78 (-0.29%) ▼|INTC131.24-1.04 (-0.79%) ▼|INTU267.81+9.76 (+3.78%) ▲|ISRG403.88+0.70 (+0.17%) ▲|JNJ239.61+0.53 (+0.22%) ▲|JPM332.93-1.22 (-0.36%) ▼|KO80.91+0.60 (+0.75%) ▲|LIN518.29+6.03 (+1.18%) ▲|LLY1,109.84+2.76 (+0.25%) ▲|LMT497.34-6.34 (-1.26%) ▼|LOW220.94+7.40 (+3.47%) ▲|LRCX367.50-3.83 (-1.03%) ▼|MA495.59+7.52 (+1.54%) ▲|MCD274.87+3.21 (+1.18%) ▲|MDLZ61.99+0.93 (+1.52%) ▲|MDT80.62-0.01 (-0.01%) ▼|META560.45-1.75 (-0.31%) ▼|MMM166.27+4.43 (+2.74%) ▲|MO72.01+0.40 (+0.56%) ▲|MRK120.49+0.89 (+0.74%) ▲|MS221.30-4.73 (-2.09%) ▼|MSFT372.07-1.87 (-0.50%) ▼|MU1,029.53-22.24 (-2.11%) ▼|NEE87.10+0.67 (+0.78%) ▲|NFLX72.74-0.09 (-0.12%) ▼|NKE41.84-0.55 (-1.29%) ▼|NOW94.38-1.57 (-1.63%) ▼|NVDA198.63-1.37 (-0.69%) ▼|ORCL158.00-7.17 (-4.34%) ▼|PEP142.44+0.39 (+0.27%) ▲|PFE24.02-0.71 (-2.85%) ▼|PG152.30+1.44 (+0.95%) ▲|PLTR114.32-2.38 (-2.04%) ▼|PM177.92-0.77 (-0.43%) ▼|QCOM196.60-7.53 (-3.69%) ▼|RTX186.37-0.02 (-0.01%) ▼|SBUX104.22+3.17 (+3.14%) ▲|SCHW91.81-1.36 (-1.46%) ▼|SO95.05+0.12 (+0.13%) ▲|SPG220.53+3.79 (+1.75%) ▲|T22.44-0.38 (-1.64%) ▼|TMO490.90+21.55 (+4.59%) ▲|TMUS182.91-1.66 (-0.90%) ▼|TSLA377.36-4.25 (-1.11%) ▼|TXN303.70-0.66 (-0.22%) ▼|UBER74.02+4.35 (+6.24%) ▲|UNH404.57-4.69 (-1.14%) ▼|UNP260.11+1.50 (+0.58%) ▲|UPS105.06-0.78 (-0.73%) ▼|USB60.14+0.09 (+0.14%) ▲|V332.83+4.35 (+1.32%) ▲|VZ45.68-1.06 (-2.26%) ▼|WFC84.22+0.09 (+0.11%) ▲|WMT119.43+0.01 (+0.01%) ▲|XOM136.36-3.38 (-2.42%) ▼|
27.5 C
New York
Wednesday, June 24, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1marketreleases

Nord Anglia Education’s Class of 2025 Heading to the World’s Top Universities

LONDON, July 4, 2025 /PRNewswire/ -- Leading international schools group Nord Anglia Education today announced that its Class of 2025 has secured places at many...

DoH, USCF and IGI Explore Establishing the World’s first-of-their kind Centres for Genome Surgery

On the sidelines of a high-level U.S. visit ABU DHABI, UAE, July 4, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator...

XTEP Ignites Global Night Running Frenzy: Over 1,000 Runners Chase Summer PBs in “Acceleration” Night-Training Footwear

Xiamen, China, July 4, 2025 /PRNewswire/ -- Beginning June 10, over 1,000 runners across China, Vietnam, Malaysia, Kazakhstan, Norway, and France laced up for...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management. 
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

AAPA Statement on Passage of the “Big Beautiful Bill”

ALEXANDRIA, Va., July 3, 2025 /PRNewswire/ -- The American Academy of Physician Associates (AAPA) President and Chair of the Board, Todd Pickard, DMSc, PA-C,...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

BioLab Holdings, Inc. Launches Multicenter Clinical Trial to Evaluate Amnion Grafts for Chronic Wounds

Study Will Assess Real-World Effectiveness of Tri-Layer and Single-Layer Amnion Grafts in Treating Diabetic Foot and Venous Leg Ulcers PHOENIX, July 3, 2025...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers